Autoimmune epilepsy: peculiarity of the course in childhood (literature review)

October 27, 2021
983
Resume

Understanding of autoimmune epilepsy has evolved significantly over the past decades with the discovery of several neuronal autoantibodies and improvement of understanding of these immune-mediated conditions. It has been shown that some patients with epilepsy of unknown etiology have an autoimmune cause. In most patients with autoimmune epilepsy, the disease debuts acutely, with the onset of refractory to conventional antiepileptic therapy seizures, along with subacute progressive decline in cognitive function, behavioral and/or mental disturbances. Autoimmune epilepsy in children is associated with neuronal antibodies, mostly in the structure of autoimmune encephalitis, which are rare conditions (mostly anti-NMDAR-encephalitis and acute disseminated encephalomyelitis), which have better prognosis with timely introduced immunosuppressive treatment. An overview of modern literature data is presented.

References

  • 1. Ong M.S., Kohane I.S., Cai T. et al. (2014) Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol.,71(5): 569–574. DOI: 10.1001/jamaneurol.2014.188.
  • 2. Camfield P., Camfield C. (2015) Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord., 17(2): 117–123. doi: 10.1684/epd.2015.0736.
  • 3. Brodie M.J., Zuberi S.M., Scheffer I.E., Fisher R.S. (2018) The 2017 ILAE classification of seizure types and the epilepsies: what do people with epilepsy and their caregivers need to know? Epileptic. Disord., 20(2): 77–87. DOI: 10.1684/epd.2018.0957.
  • 4. Dubey D., Pittock S.J., McKeon A. (2019) Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. Epilepsia, 60(2): 367–369. DOI: 10.1111/epi.14649.
  • 5. Dubey D., Alqallaf A., Hays R. et al. (2017) Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology. JAMA Neurol., 74(4): 397–402. DOI: 10.1001/jamaneurol.2016.5429.
  • 6. Scheffer I.E., Berkovic S., Capovilla G. et al. (2017) ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 58(4): 512–521. DOI: 10.1111/epi.13709.
  • 7. Suleiman J., Dale R.C. (2015) The recognition and treatment of autoimmune epilepsy in children. Dev. Med. Child. Neurol., 57: 431–440. DOI: 10.1111/dmcn.12647.
  • 8. de Bruijn M.A.A.M., Bruijstens A.L., Bastiaansen A.E.M. et al. (2020) Pediatric autoimmune encephalitis: Recognition and diagnosis. Neurol. Neuroimmunol. Neuroinflamm., 7(3): e682. DOI: 10.1212/NXI.0000000000000682.
  • 9. Dalmau J., Tüzün E., Wu H. et al. (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol., 61(1): 25–36. DOI: 10.1002/ana.2105.
  • 10. Titulaer M.J., McCracken L., Gabilondo I. et al. (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol., 12(2): 157–165. DOI: 10.1016/S1474-4422(12)70310-1.
  • 11. Dalmau J., Geis C., Graus F. (2017) Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol. Rev., 97(2): 839–887. https://doi.org/10.1152/physrev.00010.2016.
  • 12. Lancaster E., Dalmau J. (2012) Neuronal autoantigens — pathogenesis, associated disorders and antibody testing. Nat. Rev. Neurol., 8: 380–390. DOI:10.1038/nrneurol.2012.99.
  • 13. Lai M., Huijbers M.G., Lancaster E. (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol., 9(8): 776–785. doi:10.1016/S1474-4422(10)70137-X.
  • 14. Hutchinson M., Waters P., McHugh J. et al. (2008) Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology, 71(16): 1291–1292. doi: 10.1212/01.wnl.0000327606.50322.f0.
  • 15. Lancaster E., Martinez-Hernandez E., Titulaer M.J. et al. (2011) Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology, 18: 1698–1701. doi:10.1212/WNL.0b013e3182364a44.
  • 16. Netravathi M. (2019) Seronegative Autoimmune Encephalitis — A Diagnostic and Therapeutic Dilemma. Ann. Indian Acad. Neurol., 22(4):369-370. doi: 10.4103/aian.AIAN_485_19.
  • 17. Graus F., Titulaer M.J., Balu R. et al. (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol., 15: 391–404. DOI: 10.1016/S1474-4422(15)00401-9.
  • 18. Dalmau J., Graus F. (2018) Antibody-Mediated Encephalitis. New Eng. J. Med., 378(9): 840–851. doi:10.1056/NEJMra1708712.
  • 19. Cellucci T., Mater H.V., Graus F. et al. (2020) Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol. Neuroimmunol. Neuroinflamm., 7(4): DOI:10.1212/NXI.0000000000000663.
  • 20. Hacohen Y., Wright S., Waters P. et al. (2013) Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J. Neurol. Neurosurg. Psychiatr., 84(7): 748–755. doi:10.1136/jnnp-2012-303807.
  • 21. Goldberg E.M., Titulaer M., de Blank P.M. et al. (2014) Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature. Pediatr. Neurol., 50(2): 181–184. doi: 10.1016/j.pediatrneurol.2013.10.002.
  • 22. Armangue T., Titulaer M.J., Málaga I. et al. (2013) Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J. Pediatr., 12: 157–165. DOI: 10.1016/j.jpeds.2012.10.011.
  • 23. Bartels F., Krohn S., Nikolaus M. et al. (2020) Clinical and MRI Outcome Predictors in Pediatric Anti‐NMDA Receptor Encephalitis. Ann. Neurol., 88: 148–159. DOI:10.1002/ana.25754.
  • 24. Armangue T., Petit-Pedrol M., Dalmau J. (2012) Autoimmune encephalitis in children. J. Child. Neurol., 27: 1460–1469.doi: 10.1177/0883073812448838.
  • 25. Jeannin-Mayer S., André-Obadia N., Rosenberg S. (2018) EEG analysis in anti-NMDA receptor encephalitis: description of typical patterns (https://www.sciencedirect.com/science/article/pii/S1388245718313725. Manuscript_7f354bc216919151097eb41a243fe710).
  • 26. Hacohen Y., Wong Y.Y., Lechner Ch. et al. (2018) Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol., 75(4): 478–487. doi: 10.1001/jamaneurol.2017.4601.
  • 27. Baumann M., Sahin K., Lechner C. et al. (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J. Neurol. Neurosurg. Psychiatr., 86(3): 265–272. doi:10.1136/jnnp-2014-308346.
  • 28. Matesanz S., Kotch C., Perrone C. et al. (2019) Expanding the MOG phenotype: Brainstem encephalitis with punctate and curvilinear enhancement. Neurol. Neuroimmunol. Neuroinflamm, 6: e619. doi: 10.1212/NXI.0000000000000619.
  • 29. Budhram A., Mirian A., Le C. et al. (2019) Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J. Neurol., 266: 2481–2487. DOI: 10.1007/s00415-019-09440-8.
  • 30. Patterson K., Iglesias E., Nasrallah M. et al. (2019) Anti-MOG encephalitis mimicking small vessel CNS vasculitis. Neurol. Neuroimmunol. Neuroinflamm., 6: e538. DOI: 10. 1212/NXI.0000000000000538.
  • 31. Zhong X., Zhou Y., Chang Y. et al. (2019) Seizure and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Encephalomyelitis in a Retrospective Cohort of Chinese Patients. Front. Neurol., 10: 415. DOI: 10.3389/fneur.2019.00415. eCollection 2019.
  • 32. Spatola M., Petit-Pedrol M., Simabakuro M.M. et al. (2017) Investigations in GABAA receptor antibody-associated encephalitis. Neurology, 88: 1012–1020. DOI: 10.1212/WNL.0000000000003713.
  • 33. Petit-Pedrol M., Armangue T., Peng X. et al. (2014) Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAa receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies. Lancet Neurol., 13: 276–286. DOI: 10.1016/S1474-4422(13)70299-0.
  • 34. Lancaster E., Lai M., Peng X. et al. (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol., 9(1):67-76. doi: 10.1016/S1474-4422(09)70324-2.
  • 35. Hoftberger R., Titulaer M.J., Sabater L. et al. (2013) Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology, 81: 1500–1506. DOI: 10.1212/WNL.0b013e3182a9585f.
  • 36. Kruer M.C., Hoeftberger R., Lim K.Y. et al. (2014) Aggressive course in encephalitis with opsoclonus, ataxia, chorea and seizures. JAMA Neurol., 71: 620–623. DOI: 10.1001/jamaneurol.2013.4786.
  • 37. Barbagallo M., Vitaliti G., Pavone P. et al. (2017) Pediatric Autoimmune Encephalitis. J. Pediatr. Neurosci., 12(2): 130–134. DOI: 10.4103/jpn.JPN_185_16.
  • 38. Mishra N., Rodan L.H., Nita D.A. et al. (2014) Anti-glutamic acid decarboxylase antibody associated limbic encephalitis in a child: expanding the spectrum of pediatric inflammatory brain diseases. J. Child. Neurol., 29: 677–683. DOI: 10.1177/0883073813500527.
  • 39. Gresa-Arribas N., Ariño H., Martínez-Hernández E. et al. (2015) Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS One, 10: e0121364. DOI: 10.1371/journal.pone.0121364.
  • 40. Bien C.G., Bien C.I. (2020) Autoimmune encephalitis in children and Adolescents. Neurol. Res. Pract., 2: 4. doi.org/10.1186/s42466-019-0047-8.
  • 41. Barbagallo M., Vitaliti G., Pavone P. et al. (2017) Pediatric Autoimmune Encephalitis. J. Pediatr. Neurosci., 12(2): 130–134. DPI: 10.4103/jpn.JPN_185_16.
  • 42. Tatencloux S., Chretien P., Rogemond V. et al. (2015) Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Dev. Med. Child. Neurol., 57: 95–99. DOI: 10.1111/dmcn.12545.
  • 43. Yeghiazaryan N.S., Zara F., Capovilla G. et al. (2012) Pyridoxine-dependent epilepsy: An under-recognised cause of intractable seizures. J. Paediatr. Child. Health, 48: E113–E115. DOI: 10.1111/j.1440-1754.2010.01866.x.
  • 44. Suleiman J., Wright S., Gill D. et al. (2013) Autoantibodies to neuronal antigens in children with new-onset seizures classified according to the revised ILAE organization of seizures and epilepsies. Epilepsia, 54(12): 2091–2100. doi:10.1111/epi.12405.
  • 45. Wright S., Geerts A.T., Jol-van der Zijde C.M. et al. (2016) Neuronal antibodies in pediatric epilepsy: Clinical features and long-term outcomes of a historical cohort not treated with immunotherapy. Epilepsia, 57(5): 823–831. doi:10.1111/epi.13356.
  • 46. Symonds J.D., Moloney T.C., Lang B. et al. (2020) Neuronal antibody prevalence in children with seizures under 3 years. A prospective national cohort. Neurology, 95(11). DOI: https://doi.org/10.1212/WNL.0000000000010318.